Actively Recruiting
Feasibility of Using the Neovent in Low-Resource Settings
Led by Tina Slusher · Updated on 2025-06-08
70
Participants Needed
2
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Breathing problems are a leading cause of newborn death/sickness worldwide but most of deaths are in low resources areas. Over 99% of newborn death is in countries with limited healthcare resources like Nigeria and Nepal. Background For newborns who have trouble breathing, breathing with a machine that does not require an invasive breathing tube but only small nasal tubes is associated with lower rates of lung disease and less pneumonia or lung disease than newborns who have a breathing tube going into their lungs to help their breathing. Nasal Intermittent Positive Pressure Ventilation (NIPPV) is often used in high resource countries, but these machines are expensive. NIPPV gives many newborns the extra support needed to help with trouble breathing by providing extra pressure to help more air/oxygen get into their lungs. Neovent was designed to provide NIPPV at a much lower cost than machines than conventional machines. The Neovent has been shown to be safe and the device feasible in a higher resourced nursery than found in most nurseries in Nigeria and Nepal. The primary and critical research gap this study will address is to show that investigators in lower resourced nurseries can use the Neovent thus demonstrating that this device is feasible to provide NIPPV for newborns with breathing problems without any more safety problems that those seen with the continuous positive airway pressure currently used in lower resourced nurseries in Nigeria and Nepal. Aims The investigators believe NIPPV using the Neovent is feasible for use by healthcare providers in lower resourced nurseries in Nepal and Nigeria; that NIPPV provided by Neovent will be as safe as breathing support providing by machine CPAP and newborns on Neovent will not have more nasal irritation or nose bleeds, more stomach problems, or air around their lungs than newborns on machine CPAP. Study design Newborns with mild-moderate breathing trouble whose mother/caregivers agrees will be placed on Neovent for 6 hours and monitored closely for any problems with the machine or newborn that are related to the machine especially injury to the nose, nosebleeds, swollen belly or abdomen, or air around the lungs. Sample size We plan to enroll 70 newborn infants total from both sites in Nepal and Nigeria. Next Steps The next step would be to do a study to determine if the Neovent is as good as other more expensive forms of breathing support for newborn infants.
CONDITIONS
Official Title
Feasibility of Using the Neovent in Low-Resource Settings
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants 28 days old or younger
- Infant is older than 30 weeks gestational age and/or weighs more than 1000 grams
- Infant has mild to moderate respiratory distress (Downes' score 2 - 7)
- Parent or guardian provides permission (informed consent)
You will not qualify if you...
- Congenital abnormalities that make noninvasive ventilation unsafe (e.g. diaphragmatic hernia, cleft palate, tracheo-esophageal fistula)
- Need for immediate surgery
- Suspected neuromuscular problems with decreased muscle tone
- Suspected cyanotic congenital heart disease or unstable heart condition
- Severe life-threatening condition with expected survival less than 24 hours or parents request withdrawal of care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
United Mission Hospital-Tansen
Tānsen, Palpa District, Nepal
Not Yet Recruiting
2
Ahmadu Bello University
Zaria, Kano State, Nigeria
Actively Recruiting
Research Team
T
Tina M Slusher, MD
CONTACT
I
Ibukun Sonaike, MBBS, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here